Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (98396)	11/12/2003 8:40:17 AM
From: Findit	Respond to of 208838

Good news for BOCX holders - Wednesday November 12, 8:05 am ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Nov. 12, 2003--BioCurex Inc. (OTCBB:BOCX - News) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People's Republic of China. The patent covers the technologies used in the Company's Histo-RECAF(TM) and Cryo-RECAF(TM) kits as well as (Serum-RECAF(TM)) a cancer diagnostic blood test. Further, the patent protects other cancer diagnostic applications such as leukemia to be developed in a near future. Dr. Ricardo Moro, BioCurex's CEO stated: "China's healthcare market is one of the most dynamic and rapidly changing in the world and that creates abundant opportunities for foreign companies. The Chinese healthcare market is generally underestimated. For example, China is now estimated to have more CT instruments than the United States. The healthcare industry in China has posted double-digit (16 percent) average growth, annually, for a decade. China's transition into a free market economy, coupled with drastic reforms in the health sector and intellectual property protection have increased business opportunities for small and medium-sized foreign pharmaceutical, biotechnology and medical companies." In-vivo RECAF(TM) applications, such as cancer imaging, therapy and vaccination remain pending under a continuation in part of the original application. Similar patents have already been issued in the United States, Australia and Russia and they are pending in most European countries, Canada and Japan. According to a report from Genesis Technology Group, China's drug sales reached US$6.8 billion in 2002, and are expected to rise to US$14 billion in 2005 and to US$24 billion in 2010. The pharma revenue in China is about US$20 billion, of which approximately 48%, 30% and 22% come from the sales of joint venture, domestic and imported products, respectively. The size of the industry will equal that of the United States by 2020. The Globoscan 2000 cancer database states that there are about 1.9 million new cases and about 1.4 million deaths annually from cancer in China. With a population of approximately 1.3 billion, China is a vast market for cancer therapies. Cancer became the main cause of death in China in 1996. China is the fastest growing pharmaceutical market in the world and currently ranks as the ninth largest pharmaceutical market with nearly US$7 billion in sales in 2001. China's changing healthcare environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. About BioCurex: BioCurex Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from its Web site.